Nadia Dac
Corporate Officer/Principal en OMEROS CORPORATION .
Perfil
Nadia Dac currently works at Omeros Corp., as Chief Commercial Officer from 2021.
Ms. Dac also formerly worked at Auxilium Pharmaceuticals LLC, as Vice President-Marketing from 2013 to 2014, AbbVie, Inc., as VP-Global Specialty Commercial Development from 2014 to 2019, Novartis AG, as VP-Neuroscience Professional Relations from 2009 to 2013, and Lundbeck Seattle BioPharmaceuticals, Inc., as Chief Commercial Officer from 2019 to 2020.
Ms. Dac received her undergraduate degree from Rutgers State University of New Jersey.
Cargos activos de Nadia Dac
| Empresas | Cargo | Inicio |
|---|---|---|
| OMEROS CORPORATION | Corporate Officer/Principal | 26/01/2021 |
Antiguos cargos conocidos de Nadia Dac.
| Empresas | Cargo | Fin |
|---|---|---|
| ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/06/2020 |
| ABBVIE INC. | Corporate Officer/Principal | 01/03/2019 |
| AUXILIUM PHARMACEUTICALS, INC. | Sales & Marketing | 01/09/2014 |
| NOVARTIS AG | Corporate Officer/Principal | 01/01/2013 |
Formación de Nadia Dac.
| Rutgers State University of New Jersey | Undergraduate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| OMEROS CORPORATION | Health Technology |
| ABBVIE INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| Empresas privadas | 2 |
|---|---|
Auxilium Pharmaceuticals LLC
 Auxilium Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Auxilium Pharmaceuticals LLC develops and markets pharmaceutical products. It specializes in men's healthcare area and has product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas. The firm products include edex, Osbon, ErecAid, STENDRA, TESTOPEL, XIAFLEX and Testim. The company was founded by Gerri A. Henwood and Jane Holmes Hollingsworth in 1999 and is headquartered in Chesterbrook, PA. | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
- Bolsa de valores
- Insiders
- Nadia Dac
